Quality-adjusted life years in cancer: pros, cons, and alternatives

Authors


Joseph Menzin, Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451, USA (e-mail: jmenzin@bhei.com).

Abstract

WOODWARD R.M., MENZIN J. & NEUMANN P.J. (2013) European Journal of Cancer Care22, 12–19

Quality-adjusted life years in cancer: pros, cons, and alternatives

High and rising cancer treatment costs have forced a discussion about the use of cost-effectiveness analyses and other approaches to assess the value of cancer care. Oncologists have traditionally resisted using economic considerations in day-to-day medical considerations, though unavoidably their decisions have important resource implications, and increasingly economic realities are impacting their actions. In this paper, we summarise the use of the quality-adjusted life years to assess the value of cancer care and suggest potential ways to improve upon value measurement in cancer coverage and reimbursement decisions.

Ancillary